Medical/Pharmaceuticals
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...
2025-10-27 08:00
2550
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
* Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; * Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY * Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; * Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY * Q1-Q3 Net Profit Attributa...
2025-10-26 15:53
7211
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of pa...
2025-10-25 15:00
3661
Beyond Recovery: QUINEAR QN-071A Brings Professional Compression Therapy Home for Holiday Deals
NEW YORK, Oct. 24, 2025 /PRNewswire/ -- When recovery becomes the new performance edge. True progress doesn't happen during exertion — it begins in recovery. For years, QUINEAR has led the evolution of professional-grade compression systems, making clinical technology accessible to everyday athl...
2025-10-25 00:07
2421
Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance
* OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease * DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide compatibi...
2025-10-24 20:00
1972
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) onOctober 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO...
2025-10-24 16:40
1474
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanci...
2025-10-24 07:30
3361
METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has...
2025-10-23 21:21
3296
HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
* Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. * Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Hanch...
2025-10-23 19:00
3325
International Youth Explore the Wisdom of Traditional Chinese Medicine Zhangshu National Pharma Fair Opens a New Chapter in Cultural Experience
ZHANGSHU, China, Oct. 23, 2025 /PRNewswire/ -- A report from Jiangxi International Communication Center (JXICC): "Without Zhangshu, medicines are incomplete; without Zhangshu, medicines lack efficacy." OnOctober 16, 2025, Jiangxi's Zhangshu Qihuang Town was bustling with crowds as the 56th Nation...
2025-10-23 14:46
2094
MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring
SÃO PAULO, Oct. 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing essential tools and technologies to drive innovation in the life sciences, has entered into a strategic partnership with Eva Holding Group, a Brazilian group operating in genomics applied to hum...
2025-10-23 11:30
3304
Charming Medical Limited Announces Closing of Initial Public Offering
HONG KONG, Oct. 22, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), aHong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the closing of its initial public offering (the "Offering") of 1,600,000 Class A ordin...
2025-10-23 00:51
2693
SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging
LAS VEGAS, Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company fromTaiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which w...
2025-10-23 00:00
2984
The Blood Center in New Orleans modernizes platelet processing with FDA-cleared automation from Terumo Blood and Cell Technologies
— Second U.S. site to deploy the Reveos™ system, boosting platelet supply and reducing waste LAKEWOOD, Colo., Oct. 22, 2025 /PRNewswire/ -- To help address platelet shortages and streamline blood center operations, The Blood Center inNew Orleans has become the second U.S. blood center to impleme...
2025-10-22 22:39
2112
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that theBlood published the latest result...
2025-10-22 19:39
2315
LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient
SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks...
2025-10-22 14:28
1802
Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology
TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku,Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku,Tokyo). T...
2025-10-22 14:00
1397
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
* The only company from pharmaceutical industry selected for inclusion in the Index * Also included in HSI ESG Index and Hang Seng ESG 50 Index * Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a lea...
2025-10-22 08:30
3669
Charming Medical Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq
HONG KONG, Oct. 21, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), aHong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced the pricing of its initial public offering (the "Offering") of 1,600,000 Class A ordin...
2025-10-21 23:00
2502
HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...
2025-10-21 19:00
2604
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 320 media titles]
2026-08-28 09:01Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36